Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer

References

Adamopoulos, P.G., Kontos, C.K., and Scorilas, A. (2017). Molecular cloning of novel transcripts of human kallikrein-related peptidases 5, 6, 7, 8 and 9 (KLK5–KLK9), using next-generation sequencing. Sci. Rep. 7, 17299–17313.10.1038/s41598-017-16269-6Search in Google Scholar PubMed PubMed Central

Akram, M., Iqbal, M., Daniyal, M., and Khan, A.U. (2017). Awareness and current knowledge of breast cancer. Biol. Res. 50, 33–56.10.1186/s40659-017-0140-9Search in Google Scholar PubMed PubMed Central

Avgeris, M., Mavridis, K., and Scorilas, A. (2010). Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol. Chem. 391, 505–511.10.1515/bc.2010.056Search in Google Scholar PubMed

Avgeris, M., Papachristopoulou, G., Polychronis, A., and Scorilas, A. (2011). Down-regulation of kallikrein-related peptidase 5 (KLK5) expression in breast cancer patients: a biomarker for the differential diagnosis of breast lesions. Clin. Proteomics 8, 5–17.10.1186/1559-0275-8-5Search in Google Scholar PubMed PubMed Central

Avgeris, M., Mavridis, K., and Scorilas, A. (2012). Kallikrein-related peptidases in prostate, breast, and ovarian cancers: from pathobiology to clinical relevance. Biol. Chem. 393, 301–317.10.1515/hsz-2011-0260Search in Google Scholar PubMed

Bao, J., Zhu, L., Zhu, Q., Su, J., Liu, M., and Huang, W. (2016). SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer. Oncol. Lett. 12, 2409–2416.10.3892/ol.2016.4988Search in Google Scholar PubMed PubMed Central

Beaufort, N., Debela, M., Creutzburg, S., Kellermann, J., Bode, W., Schmitt, M., Pidard, D., and Magdolen, V. (2006). Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol. Chem. 87, 217–222.10.1515/BC.2006.029Search in Google Scholar PubMed

Blaber, S.I., Yoon, H., Scarisbrick, I.A., Juliano, M.A., and Blaber, M. (2007). The autolytic regulation of human kallikrein-related peptidase 6. Biochemistry 46, 5209–5217.10.1021/bi6025006Search in Google Scholar PubMed PubMed Central

Black, M.H., Giai, M., Ponzone, R., Sismondi, P., Yu, H., and Diamandis, E.P. (2000). Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin. Cancer Res. 6, 467–473.Search in Google Scholar

Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., and Kuliopulos, A. (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303–313.10.1016/j.cell.2004.12.018Search in Google Scholar PubMed

Borchert, G.H., Melegos, D.N., Tomlinson, G., Giai, M., Roagna, R., Ponzone, R., Sgro, L., and Diamandis, E.P. (1997). Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br. J. Cancer 76, 1087–1094.10.1038/bjc.1997.512Search in Google Scholar PubMed PubMed Central

Borgoño, C.A., Grass, L., Soosaipillai, A., Yousef, G.M., Petraki, C.D., Howarth, D.H., Fracchioli, S., Katsaros, D., and Diamandis, E.P. (2003). Human kallikrein 14: a new potential biomarker for ovarian and breast cancer. Cancer Res. 63, 9032–9041.Search in Google Scholar

Borgoño, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257–280.10.1158/1541-7786.257.2.5Search in Google Scholar

Borgoño, C.A., Michael, I.P., Shaw, J.L., Luo, L.Y., Ghosh, M.C., Soosaipillai, A., Grass, L., Katsaros, D., and Diamandis, E.P. (2007). Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J. Biol. Chem. 282, 2405–2422.10.1074/jbc.M608348200Search in Google Scholar

Cereda, V., Formica, V., Menghi, A., Pellicori, S., and Roselli, M. (2015). Kallikrein-related peptidases targeted therapies in prostate cancer: perspectives and challenges. Expert Opin. Investig. Drugs 9, 1–19.10.1517/13543784.2015.1035708Search in Google Scholar

Çetin Sorkun, H., Akbulut, M., Enli, Y., Tepeli, E., Özkan, S., and Erdem, E. (2016). Quantitative comparison of immunohistochemical and PCR analysis of midkine expression in breast cancer types and serum midkine level. Turk. J. Med. Sci. 46, 219–227.10.3906/sag-1411-158Search in Google Scholar

Chang, A., Yousef, G.M., Jung, K., Rajpert-De Meyts, E., and Diamandis, E.P. (2001). Identification and molecular characterization of five novel kallikrein gene 13 (KLK13; KLK-L4) splice variants: differential expression in the human testis and testicular cancer. Anticancer Res. 21, 3147–3152.Search in Google Scholar

Chang, A., Yousef, G.M., Scorilas, A., Grass, L., Sismondi, P., Ponzone, R., and Diamandis, E.P. (2002). Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br. J. Cancer 86, 1457–1464.10.1038/sj.bjc.6600283Search in Google Scholar

Collier, M.E., Li, C., and Ettelaie, C. (2008). Influence of exogenous tissue factor on estrogen receptor alpha expression in breast cancer cells: involvement of beta1-integrin, PAR2, and mitogen-activated protein kinase activation. Mol. Cancer Res. 6, 1807–1818.10.1158/1541-7786.MCR-08-0109Search in Google Scholar

Dash, P., Pati, S., Mangaraj, M., Sahu, P.K., and Mohapatra, P.C. (2011). Serum total PSA and free PSA in breast tumors. Indian J. Clin. Biochem. 26, 182–186.10.1007/s12291-011-0115-5Search in Google Scholar

Demoulin, J. and Essaghir, A. (2014). PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev. 25, 273–283.10.1016/j.cytogfr.2014.03.003Search in Google Scholar

Dhar, S., Bhargava, R., Yunes, M., Li, B., Goyal, J., Naber, S.P., Wazer, D.E., and Band, V. (2001). Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin. Cancer Res. 7, 3393–3398.Search in Google Scholar

Diamandis, E.P. and Yousef, G.M. (2001). Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert. Rev. Mol. Diagn. 1, 182–190.10.1586/14737159.1.2.182Search in Google Scholar

Diamandis, E.P., Yousef, G.M., Luo, L.Y., Magklara, A., and Obiezu, C.V. (2000a). The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol. Metab. 11, 54–60.10.1016/S1043-2760(99)00225-8Search in Google Scholar

Diamandis, E.P., Yousef, G.M., Soosaipillai, A.R., Grass, L., Porter, A., Little, S., and Sotiropoulou, G. (2000b). Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin. Biochem. 33, 369–375.10.1016/S0009-9120(00)00145-4Search in Google Scholar

Dong, Y., Stephens, C., Walpole, C., Swedberg, J.E., Boyle, G.M., Parsons, P.G., McGuckin, M.A., Harris, J.M., and Clements, J.A. (2013). Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One 8, e57056.10.1371/journal.pone.0057056Search in Google Scholar PubMed PubMed Central

Ehrenfeld, P., Manso, L., Pavicic, M.F., Matus, C.E., Borquez, C., Lizama, A., Sarmiento, J., Poblete, M.T., Bhoola, K.D., Naran, A., et al. (2014). Bioregulation of kallikrein-related peptidases 6, 10 and 11 by the kinin B₁ receptor in breast cancer cells. Anticancer Res. 34, 6925–6938.Search in Google Scholar

Ejaz, S., Nasim, F.U., Ashraf, M., and Ahmad, G. (2017). Down-regulation of hK7 in the sera of breast cancer and benign breast disease patients. Heliyon 3, e00356.10.1016/j.heliyon.2017.e00356Search in Google Scholar PubMed PubMed Central

Ekholm, I.E., Brattsand, M., and Egelrud, T. (2000). Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? J. Invest. Dermatol. 114, 56–63.10.1046/j.1523-1747.2000.00820.xSearch in Google Scholar PubMed

Ewan King, L., Li, X., Cheikh Saad Bouh, K., Pedneault, M., and Chu, C.W. (2007). Human kallikrein 10 ELISA development and validation in breast cancer sera. Clin. Biochem. 40, 1057–1062.10.1016/j.clinbiochem.2007.05.008Search in Google Scholar PubMed

Fan, J., Tea, M.K., Yang, C., Ma, L., Meng, Q.H., Hu, T.Y., Singer, C.F., and Ferrari, M. (2016). Profiling of cross-functional peptidases regulated circulating peptides in BRCA1 mutant breast cancer. J. Proteome Res. 15, 1534–1545.10.1021/acs.jproteome.6b00010Search in Google Scholar PubMed PubMed Central

Felber, L.M., Borgoño, C.A., Cloutier, S.M., Kündig, C., Kishi, T., Ribeiro Chagas, J., Jichlinski, P., Gygi, C.M., Leisinger, H.J., Diamandis, E.P., et al. (2005). Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol. Chem. 386, 291–298.10.1515/BC.2005.035Search in Google Scholar PubMed

Fernandez, E.V., Reece, K.M., Ley, A.M., Troutman, S.M., Sissung, T.M., Price, D.K., Chau, C.H., and Figg, W.D. (2015). Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells. Mol. Pharmacol. 87, 1006–1012.10.1124/mol.114.097477Search in Google Scholar PubMed PubMed Central

Figueroa, C.D., Ehrenfeld, P., and Bhoola, K.D. (2012). Kinin receptors as targets for cancer therapy. Expert Opin. Ther. Targets 16, 299–312.10.1517/14728222.2012.662957Search in Google Scholar PubMed

Filippou, P.S., Karagiannis, G.S., Musrap, N., and Diamandis, E.P. (2016). Kallikrein-related peptidases (KLKs) and the hallmarks of cancer. Crit. Rev. Clin. Lab. Sci. 53, 277–291.10.3109/10408363.2016.1154643Search in Google Scholar PubMed

Fortier, A.H., Nelson, B.J., Grella, D.K., and Holaday, J.W. (1999). Antiangiogenic activity of prostate-specific antigen. J. Natl. Cancer Inst. 91, 1635–1640.10.1093/jnci/91.19.1635Search in Google Scholar

Gallo, D., Mantuano, E., Fabrizi, M., Ferlini, C., Mozzetti, S., De Stefano, I., and Scambia, G. (2007). Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer. Endocr. Relat. Cancer 14, 317–324.10.1677/ERC-06-0054Search in Google Scholar

Gilkes, D.M. and Semenza, G.L. (2013). Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol. 9, 1623–1636.10.2217/fon.13.92Search in Google Scholar

Green, A.R., Green, V.L., White, M.C., and Speirs, V. (1997). Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. J. Inter. Cancer 72, 937–941.10.1002/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-QSearch in Google Scholar

Guillon-Munos, A., Oikonomopoulou, K., Michel, N., Smith, C.R., Petit-Courty, A., Canepa, S., Reverdiau, P., Heuzé-Vourc’h, N., Diamandis, E.P., and Courty, Y. (2011). Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. Biol. Chem. 286, 25505–25518.10.1074/jbc.M110.213231Search in Google Scholar

Guimarães, K.G., de Freitas, R.P., Ruiz, A.L., Fiorito, G.F., de Carvalho, J.E., da Cunha, E.F., Ramalho, T.C., and Alves, R.B. (2016). Synthesis, antiproliferative activities, and computational evaluation of novel isocoumarin and 3,4-dihydroisocoumarin derivatives. Eur. J. Med. Chem. 111, 1103–1113.10.1016/j.ejmech.2016.01.051Search in Google Scholar

Guo, S., Skala, W., Magdolen, V., Brandstetter, H., and Goettig, P. (2014a). Sweetened kallikrein-related peptidases (KLKs): glycan trees as potential regulators of activation and activity. Biol. Chem. 395, 959–976.10.1515/hsz-2014-0140Search in Google Scholar

Guo, D., Bell, E.H., Mischel, P., and Chakravarti, A. (2014b). Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr. Pharm. Des. 20, 2619–2626.10.2174/13816128113199990486Search in Google Scholar

Hatanaka, K., Simons, M., and Murakami, M. (2011). Phosphorylation of VE-cadherin controls endothelial phenotypes via p120-catenin coupling and Rac1 activation. Am. J. Physiol. Heart Circ. Physiol. 300, H162–H172.10.1152/ajpheart.00650.2010Search in Google Scholar

Hollenberg, M.D., Hooper, J.D., Darmoul, D., and Oikonomopoulou, K. (2012). Kallikrein-related peptidases (KLKs), proteinase-mediated signaling and proteinase-activated receptors (PARs). In: Kallikrein-related Peptidases Characterization, Regulation, and Interactions within the Protease Web. V. Magdolen, C. Sommerhoff, H. Fritz and M. Schmitt, eds. (Berlin: De Gruyter), pp. 373–398.10.1515/9783110260373.373Search in Google Scholar

Holzscheiter, L., Biermann, J.C., Kotzsch, M., Prezas, P., Farthmann, J., Baretton, G., Luther, T., Tjan-Heijnen, V.C., Talieri, M., Schmitt, M., et al. (2006). Quantitative reverse transcription-PCR assay for detection of mRNA encoding full-length human tissue kallikrein 7: prognostic relevance of KLK7 mRNA expression in breast cancer. Clin. Chem. 52, 1070–1079.10.1373/clinchem.2005.065599Search in Google Scholar PubMed

Huck, L., Pontier, S.M., Zuo, D.M., and Muller, W.J. (2010). Beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc. Natl. Acad. Sci. USA 107, 15559–15564.10.1073/pnas.1003034107Search in Google Scholar PubMed PubMed Central

Ivanović, V., Demajo, M., Krtolica, K., Krajnović, M., Konstantinović, M., Baltić, V., Prtenjak, G., Stojiljković, B., Breberina, M., Nesković-Konstantinović, Z., et al. (2006). Elevated plasma TGF-β1 levels correlate with decreased survival of metastatic breast cancer patients. Clin. Chim. Acta 371, 191–193.10.1016/j.cca.2006.02.027Search in Google Scholar PubMed

Jones, T.H., Figueroa, C.D., Smith, C., Cullen, D.R., and Bhoola, K.D. (1990). Characterization of a tissue kallikrein in human prolactin-secreting adenomas. J. Endocrinol. 124, 327–331.10.1677/joe.0.1240327Search in Google Scholar PubMed

Kalinska, M., Meyer-Hoffert, U., Kantyka, T., and Potempa, J. (2016). Kallikreins – the melting pot of activity and function. Biochimie 122, 270–282.10.1016/j.biochi.2015.09.023Search in Google Scholar PubMed PubMed Central

Kapadia, C., Chang, A., Sotiropoulou, G., Yousef, G.M., Grass, L., Soosaipillai, A., Xing, X., Howarth, D.H., and Diamandis, E.P. (2003). Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin. Chem. 49, 77–86.10.1373/49.1.77Search in Google Scholar PubMed

Kioulafa, M., Kaklamanis, L., Stathopoulos, E., Mavroudis, D., Georgoulias, V., and Lianidou, E.S. (2009). Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Ann. Oncol. 20, 1020–1025.10.1093/annonc/mdn733Search in Google Scholar PubMed

Kishi, T., Grass, L., Soosaipillai, A., Shimizu-Okabe, C., and Diamandis, E.P. (2003). Human kallikrein 8: immunoassay development and identification in tissue extracts and biological fluids. Clin. Chem. 49, 87–96.10.1373/49.1.87Search in Google Scholar PubMed

Kittaneh, M., Montero, A.J., and Glück, S. (2013). Molecular profiling for breast cancer: a comprehensive review. Biomark. Cancer 5, 61–70.10.4137/BIC.S9455Search in Google Scholar PubMed PubMed Central

Klokk, T.I., Kilander, A., Xi, Z., Waehre, H., Risberg, B., Danielsen, H.E., and Saatcioglu, F. (2007). Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res. 67, 5221–5230.10.1158/0008-5472.CAN-06-4728Search in Google Scholar PubMed

Kontos, C.K. and Scorilas, A. (2012). Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin. Chem. Lab. Med. 50, 1877–1891.10.1515/cclm-2012-0247Search in Google Scholar PubMed

Koumandou, V.L. and Scorilas, A. (2013). Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms. PLoS One 8, e68074.10.1371/journal.pone.0068074Search in Google Scholar PubMed PubMed Central

Kryza, T., Lalmanach, G., Lavergne, M., Lecaille, F., Reverdiau, P., Courty, Y., and Heuzé-Vourc’h, N. (2013). Pro-angiogenic effect of human kallikrein-related peptidase 12 (KLK12) in lung endothelial cells does not depend on kinin-mediated activation of B2 receptor. Biol. Chem. 394, 385–391.10.1515/hsz-2012-0291Search in Google Scholar PubMed

Kryza, T., Achard, C., Parent, C., Marchand-Adam, S., Guillon-Munos, A., Iochmann, S., Korkmaz, B., Respaud, R., Courty, Y., and Heuzé-Vourc’h, N. (2014). Angiogenesis stimulated by human kallikrein-related peptidase 12 acting via a platelet-derived growth factor B-dependent paracrine pathway. FASEB J. 28, 740–751.10.1096/fj.13-237503Search in Google Scholar PubMed

Kryza, T., Silva, M.L., Loessner, D., Heuzé-Vourc’h, N., and Clements, J.A. (2016). The kallikrein-related peptidase family: dysregulation and functions during cancer progression. Biochimie 122, 283–299.10.1016/j.biochi.2015.09.002Search in Google Scholar PubMed

Kulasingam, V. and Diamandis, E.P. (2007). Glucocorticoid receptor-mediated expression of kallikrein 10 in human breast cancer cell lines. Biol. Chem. 388, 1113–1119.10.1515/BC.2007.103Search in Google Scholar PubMed

Lahlou, H. and Muller, W.J. (2011). β1-Integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Res. 13, 229–239.10.1186/bcr2905Search in Google Scholar PubMed PubMed Central

Lai, J., Myers, S.A., Lawrence, M.G., Odorico, D.M., and Clements J.A. (2009). Direct progesterone receptor and indirect androgen receptor interactions with the kallikrein-related peptidase 4 gene promoter in breast and prostate cancer. Mol. Cancer Res. 7, 129–141.10.1158/1541-7786.MCR-08-0218Search in Google Scholar PubMed

Larssen, P., Wik, L., Czarnewski, P., Eldh, M., Löf, L., Ronquist, K.G., Dubois, L., Freyhult, E., Gallant, C.J., Oelrich, J., et al. (2017). Tracing cellular origin of human exosomes using multiplex proximity extension assays. Mol. Cell Proteomics 16, 502–511.10.1074/mcp.M116.064725Search in Google Scholar PubMed PubMed Central

Le Guelte, A., Dwyer, J., and Gavard, J. (2011). Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol. Cell 103, 593–605.10.1042/BC20110069Search in Google Scholar PubMed

Li, B., Goyal, J., Dhar, S., Dimri, G., Evron, E., Sukumar, S., Wazer, D.E., and Band, V. (2001). CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 61, 8014–8021.Search in Google Scholar

Li, X., Liu, J., Wang, Y., Zhang, L., Ning, L., and Feng, Y. (2009). Parallel underexpression of kallikrein 5 and kallikrein 7 mRNA in breast malignancies. Cancer Sci. 100, 601–617.10.1111/j.1349-7006.2009.01090.xSearch in Google Scholar PubMed

Li, X.J., Ren, Z.J., and Tang, J.H. (2014). MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death. Dis. 5, e1327.10.1038/cddis.2014.270Search in Google Scholar PubMed PubMed Central

Li, F., Tian, P., Zhang, J., and Kou, C. (2015). The clinical and prognostic significance of midkine in breast cancer patients. Tumour Biol. 36, 9789–9794.10.1007/s13277-015-3710-xSearch in Google Scholar PubMed

Lin, K.S., Pan, J., Amouroux, G., Turashvili, G., Mesak, F., Hundal-Jabal, N., Pourghiasian, M., Lau, J., Jenni, S., Aparicio, S., et al. (2015). In vivo radioimaging of bradykinin receptor b1, a widely overexpressed molecule in human cancer. Cancer Res. 75, 387–393.10.1158/0008-5472.CAN-14-1603Search in Google Scholar PubMed

Liu, X.L., Wazer, D.E., Watanabe, K., and Band, V. (1996). Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 56, 3371–3379.Search in Google Scholar

Liu, Q., Wang, W., Yang, X., Zhao, D., Li, F., and Wang, H. (2016). MicroRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancer. Oncol. Rep. 36, 189–196.10.3892/or.2016.4788Search in Google Scholar PubMed PubMed Central

Loessner, D., Quent, V.M., Kraemer, J., Weber, E.C., Hutmacher, D.W., Magdolen, V., and Clements, J.A. (2012). Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance. Gynecol. Oncol. 127, 569–578.10.1016/j.ygyno.2012.09.001Search in Google Scholar PubMed

Louie, E., Chen, X.F., Coomes, A., Ji, K., Tsirka, S., and Chen, E.I. (2013). Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene 32, 4064–4077.10.1038/onc.2012.417Search in Google Scholar PubMed PubMed Central

Lundwall, A. (2013). Old genes and new genes: the evolution of the kallikrein locus. Thromb. Haemost. 110, 469–475.10.1160/TH12-11-0851Search in Google Scholar PubMed

Lundwall, l.A. and Brattsand, M. (2008). Kallikrein-related peptidases. Cell Mol. Life Sci. 65, 2019–2038.10.1007/s00018-008-8024-3Search in Google Scholar PubMed

Luo, L.Y., Grass, L., and Diamandis, E.P. (2000). The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. Anticancer Res. 20, 981–986.Search in Google Scholar

Luo, L.Y., Diamandis, E.P., Look, M.P., Soosaipillai, A.P., and Foekens, J.A. (2002). Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br. J. Cancer 86, 1790–1796.10.1038/sj.bjc.6600323Search in Google Scholar PubMed PubMed Central

Luo, L.Y., Yousef, G., and Diamandis, E.P. (2003). Human tissue kallikreins and testicular cancer. APMIS. 111, 225–232.10.1034/j.1600-0463.2003.11101261.xSearch in Google Scholar

Madhusudan, S., Foster, M., Muthuramalingam, S.R., Braybrooke, J.P., Wilner, S., Kaur, K., Han, C., Hoare, S., Balkwill, F., Talbot, D.C., et al. (2004). A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin. Cancer Res. 10, 6528–6534.10.1158/1078-0432.CCR-04-0730Search in Google Scholar

Magklara, A., Grass, L., and Diamandis, E.P. (2000). Differential steroid hormone regulation of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) in breast cancer cell lines. Breast Cancer Res. Treat. 59, 263–270.10.1023/A:1006304518750Search in Google Scholar

Magklara, A., Mellati, A.A., Wasney, G.A., Little, S.P., Sotiropoulou, G., Becker, G.W., and Diamandis, E.P. (2003). Characterization of the enzymatic activity of human kallikrein 6: autoactivation, substrate specificity, and regulation by inhibitors. Biochem. Biophys. Res. Commun. 307, 948–955.10.1016/S0006-291X(03)01271-3Search in Google Scholar

Mangé, A., Desmetz, C., Berthes, M.L., Maudelonde, T., and Solassol, J. (2008). Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells. Biochem. Biophys. Res. Commun. 375, 107–112.10.1016/j.bbrc.2008.07.138Search in Google Scholar PubMed

Mangé, A., Dimitrakopoulos, L., Soosaipillai, A., Coopman, P., Diamandis, E.P., and Solassol, J. (2016). An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma. J. Proteomics 142, 114–121.10.1016/j.jprot.2016.04.050Search in Google Scholar PubMed

Mannello, F. and Gazzanelli, G. (2001). Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics? Breast Cancer Res. 3, 238–243.10.1186/bcr302Search in Google Scholar PubMed PubMed Central

Mashkoor, F.C., Al-Asadi, J.N., and Al-Naama, L.M. (2013). Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol. 37, 613–638.10.1016/j.canep.2013.06.009Search in Google Scholar PubMed

Mason, S.D. and Joyce, J.A. (2010). Proteolytic networks in cancer. Trends Cell. Biol. 21, 228–237.10.1016/j.tcb.2010.12.002Search in Google Scholar PubMed PubMed Central

Mian, O.Y., Wang, S.Z., Zhu, S.Z., Gnanapragasam, M.N., Graham, L., Bear, H.D., and Ginder, G.D. (2011). Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol. Cancer Res. 9, 1152–1162.10.1158/1541-7786.MCR-11-0252Search in Google Scholar PubMed PubMed Central

Michael, I.P., Sotiropoulou, G., Pampalakis, G., Magklara, A., Ghosh, M., Wasney, G., and Diamandis, E.P. (2005). Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 280, 14628–14635.10.1074/jbc.M408132200Search in Google Scholar PubMed

Michaelidou, K., Ardavanis, A., and Scorilas, A. (2015). Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival. Breast Cancer Res. Treat. 152, 323–336.10.1007/s10549-015-3470-8Search in Google Scholar PubMed

Mittal, K., Ebos, J., and Rini, B. (2014). Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. Semin. Oncol. 41, 235–251.10.1053/j.seminoncol.2014.02.007Search in Google Scholar PubMed

Mize, G.J., Wang, W., and Takayama, T.K. (2008). Prostate-specific kallikreins 2 and 4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol. Cancer Res. 6, 1043–1051.10.1158/1541-7786.MCR-08-0096Search in Google Scholar PubMed

Molina, L., Matus, C.E., Astroza, A., Pavicic, F., Tapia, E., Toledo, C., Perez, J.A., Nualart, F., Gonzalez, C.B., Burgos, R.A., et al. (2009). Stimulation of the bradykinin B(1) receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res. Treat. 118, 499–510.10.1007/s10549-009-0314-4Search in Google Scholar PubMed

Morizane, S., Yamasaki, K., Kabigting, F.D., and Gallo, R.L. (2010). Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J. Invest. Dermatol. 130, 1297–1306.10.1038/jid.2009.435Search in Google Scholar PubMed PubMed Central

Noh, H., Hong, S., and Huang, S. (2013). Role of urokinase receptor in tumor progression and development. Theranostics 3, 487–495.10.7150/thno.4218Search in Google Scholar PubMed PubMed Central

O’Day, E. and Lal, A. (2010). MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 12, 201–221.10.1186/bcr2484Search in Google Scholar PubMed PubMed Central

Obiezu, C.V. and Diamandis, E.P. (2005). Human tissue kallikrein gene family: applications in cancer. Cancer Lett. 224, 1–22.10.1016/j.canlet.2004.09.024Search in Google Scholar PubMed

Oliveras-Ferraros, C., Vazquez-Martin, A., Cuyàs, E., Corominas-Faja, B., Rodríguez-Gallego, E., Fernández-Arroyo, S., Martin-Castillo, B., Joven, J., and Menendez, J.A. (2014). Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile. Cell Cycle 13, 1132–1144.10.4161/cc.27982Search in Google Scholar PubMed PubMed Central

Paliouras, M. and Diamandis, E.P. (2006). Coordinated steroid hormone-dependent and independent expression of multiple kallikreins in breast cancer cell lines. Breast Cancer Res. Treat. 102, 7–18.10.1007/s10549-006-9312-ySearch in Google Scholar PubMed

Paliouras, M. and Diamandis, E.P. (2008). Intracellular signaling pathways regulate hormone-dependent kallikrein gene expression. Tumour Biol. 29, 63–75.10.1159/000135686Search in Google Scholar PubMed

Paltridge, J.L., Belle, L., and Khew-Goodal, l.Y. (2013). The secretome in cancer progression. Biochim. Biophys. Acta 1834, 2233–2241.10.1016/j.bbapap.2013.03.014Search in Google Scholar PubMed

Pampalakis, G. and Sotiropoulou, G. (2006). Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol. Chem. 387, 773–782.10.1515/BC.2006.097Search in Google Scholar PubMed

Pampalakis, G., Prosnikli, E., Agalioti, T., Vlahou, A., Zoumpourlis, V., and Sotiropoulou, G. (2009). A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition. Cancer Res. 69, 3779–3787.10.1158/0008-5472.CAN-08-1976Search in Google Scholar PubMed

Pampalakis, G., Obasuyi, O., Papadodima, O., Chatziioannou, A., Zoumpourlis, V., and Sotiropoulou, G. (2014). The KLK5 protease suppresses breast cancer by repressing the mevalonate pathway. Oncotarget 5, 2390–2403.10.18632/oncotarget.1235Search in Google Scholar PubMed PubMed Central

Papachristopoulou, G., Avgeris, M., and Scorilas, A. (2009). Expression analysis and study of KLK4 in benign and malignant breast tumors. Thromb. Haemost. 101, 381–387.10.1160/TH08-01-0037Search in Google Scholar

Papachristopoulou, G., Avgeris, M., Charlaftis, A., and Scorilas, A. (2011). Quantitative expression analysis and study of the novel human kallikrein-related peptidase 14 gene (KLK14) in malignant and benign breast tissues. Thromb. Haemost. 105, 131–137.10.1160/TH10-02-0092Search in Google Scholar PubMed

Papachristopoulou, G., Talieri, M., and Scorilas, A. (2013). Significant alterations in the expression pattern of kallikrein-related peptidase genes KLK4, KLK5 and KLK14 after treatment of breast cancer cells with the chemotherapeutic agents epirubicin, docetaxel and methotrexate. Tumour Biol. 34, 369–378.10.1007/s13277-012-0558-1Search in Google Scholar PubMed

Papageorgis, P., Lambert, A.W., Ozturk, S., Gao, F., Pan, H., Manne, U., Alekseyev, Y.O., Thiagalingam, A., Abdolmaleky, H.M., Lenburg, M., et al. (2010). Smad signaling is required to maintain epigenetic silencing during breast cancer progression. Cancer Res. 70, 968–978.10.1158/0008-5472.CAN-09-1872Search in Google Scholar PubMed PubMed Central

Papagerakis, P., Pannone, G., Zheng, L.I., Athanassiou-Papaefthymiou, M., Yamakoshi, Y., McGuff, H.S., Shkeir, O., Ghirtis, K., and Papagerakis, S. (2015). Clinical significance of kallikrein-related peptidase-4 in oral cancer. Anticancer Res. 35, 1861–1866.Search in Google Scholar

Paulsson, J., Ehnman, M., and Östman, A. (2014). PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol. 10, 1695–1708.10.2217/fon.14.83Search in Google Scholar PubMed

Poh, B.H., Jayaram, G., Sthaneshwar, P., and Yip, C.H. (2008). Prostate-specific antigen in breast disease. Malays. J. Pathol. 30, 43–51.Search in Google Scholar

Powers, C.A. and Hatala, M.A. (1990). Prolactin proteolysis by glandular kallikrein: in vitro reaction requirements and cleavage sites, and detection of processed prolactin in vivo. Endocrinology 127, 1916–1927.10.1210/endo-127-4-1916Search in Google Scholar PubMed

Prezas, P., Arlt, M.J., Viktorov, P., Soosaipillai, A., Holzscheiter, L., Schmitt, M., Talieri, M., Diamandis, E.P., Krüger, A., and Magdolen, V. (2006). Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol. Chem. 387, 807–811.10.1515/BC.2006.102Search in Google Scholar PubMed

Qin, W., Zhang, K., Kliethermes, B., Ruhlen, R.L., Browne, E.P., Arcaro, K.F., and Sauter, E.R. (2012). Differential expression of cancer associated proteins in breast milk based on age at first full term pregnancy. BMC Cancer 12, 100–109.10.1186/1471-2407-12-100Search in Google Scholar PubMed PubMed Central

Rajapakse, S. and Takahashi, T. (2007). Expression and enzymatic characterization of recombinant human kallikrein 14. Zoolog. Sci. 24, 774–780.10.2108/zsj.24.774Search in Google Scholar PubMed

Ramani, V.C. and Haun, R.S. (2008a). The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem. Biophys. Res. Commun. 369, 1169–1173.10.1016/j.bbrc.2008.03.021Search in Google Scholar PubMed

Ramani, V.C. and Haun, R.S. (2008b). Expression of kallikrein 7 diminishes pancreatic cancer cell adhesion to vitronectin and enhances urokinase-type plasminogen activator receptor shedding. Pancreas 37, 399–404.10.1097/MPA.0b013e31817f76f7Search in Google Scholar PubMed

Ramani, V.C., Kaushal, G.P., and Haun, R.S. (2011). Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains. Biochim. Biophys. Acta 1813, 1525–1531.10.1016/j.bbamcr.2011.05.007Search in Google Scholar PubMed PubMed Central

Ramsay, A.J., Dong, Y., Hunt, M.L., Linn, M., Samaratunga, H., Clements, J.A., and Hooper, J.D. (2008). Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression. J. Biol. Chem. 283, 12293–12304.10.1074/jbc.M709493200Search in Google Scholar PubMed

Rasheed, S.A., Teo, C.R., Beillard, E.J., Voorhoeve, P.M., Zhou, W., Ghosh, S., and Casey, P.J. (2015). MicroRNA-31 controls G protein alpha-13 (GNA13) expression and cell invasion in breast cancer cells. Mol. Cancer 14, 67–77.10.1186/s12943-015-0337-xSearch in Google Scholar PubMed PubMed Central

Rojas, K. and Stuckey, A. (2016). Breast cancer epidemiology and risk factors. Clin. Obstet. Gynecol. 59, 651–672.10.1097/GRF.0000000000000239Search in Google Scholar PubMed

Rosa, M. (2015). Advances in the molecular analysis of breast cancer: pathway toward personalized medicine. Cancer Control 22, 211–219.10.1177/107327481502200213Search in Google Scholar PubMed

Salah, Z., Maoz, M., Cohen, I., Pizov, G., Pode, D., Runge, M.S., and Bar-Shavit, R. (2005). Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J. 19, 62–72.10.1096/fj.04-2386comSearch in Google Scholar PubMed

Sandhu, R., Rein, J., D’Arcy, M., Herschkowitz, J.I., Hoadley, K.A., and Troester, M.A. (2014). Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. Carcinogenesis 35, 2567–2575.10.1093/carcin/bgu175Search in Google Scholar PubMed PubMed Central

Sano, A., Sangai, T., Maeda, H., Nakamura, M., Hasebe, T., and Ochiai, A. (2007). Kallikrein 11 expressed in human breast cancer cells releases insulin-like growth factor through degradation of IGFBP-3. Int. J. Oncol. 30, 1493–1498.10.3892/ijo.30.6.1493Search in Google Scholar

Sauter, E.R., Lininger, J., Magklara, A., Hewett, J.E., and Diamandis, E.P. (2004). Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Int. J. Cancer 108, 588–591.10.1002/ijc.11607Search in Google Scholar PubMed

Schmitt, M., Magdolen, V., Yang, F., Kiechle, M., Bayani, J., Yousef, G.M., Scorilas, A., Diamandis, E.P., and Dorn, J. (2013). Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies. Radiol. Oncol. 47, 319–329.10.2478/raon-2013-0053Search in Google Scholar PubMed PubMed Central

Schröder, F.H., Bangma, C.H., and Roobol, M.J. (2008). Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur. Urol. 53, 901–908.10.1016/j.eururo.2008.01.048Search in Google Scholar PubMed

Semenza, G.L. (2015) The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim. Biophys. Acta 1863, 382–391.10.1016/j.bbamcr.2015.05.036Search in Google Scholar PubMed PubMed Central

Shaw, J.L. and Diamandis, E.P. (2007). Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 53, 1423–1432.10.1373/clinchem.2007.088104Search in Google Scholar PubMed

Sheng, L., Anderson, P.H., Turner, A.G., Pishas, K.I., Dhatrak, D.J., Gill, P.G., Morris, H.A., and Callen, D.F. (2016). Identification of vitamin D3 target genes in human breast cancer tissue. J. Steroid Biochem. Mol. Biol. 164, 90–97.10.1016/j.jsbmb.2015.10.012Search in Google Scholar PubMed

Si, W., Li, Y., Shao, H., Hu, R., Wang, W., Zhang, K., and Yang, Q. (2016). MiR-34a inhibits breast cancer proliferation and progression by targeting Wnt1 in Wnt/β-catenin signaling pathway. Am. J. Med. Sci. 352, 191–199.10.1016/j.amjms.2016.05.002Search in Google Scholar PubMed

Sidiropoulos, M., Pampalakis, G., Sotiropoulou, G., Katsaros, D., and Diamandis, E.P. (2005). Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumor Biol. 26, 324–336.10.1159/000089290Search in Google Scholar PubMed

Sidiropoulos, K.G., White, N.M., Bui, A., Ding, Q., Boulos, P., Pampalakis, G., Khella, H., Samuel, J.N., Sotiropoulou, G., and Yousef, G.M. (2014). Kallikrein-related peptidase 5 induces miRNA-mediated anti-oncogenic pathways in breast cancer. Oncoscience 1, 709–724.10.18632/oncoscience.91Search in Google Scholar PubMed PubMed Central

Silva, R.N., Oliveira, L.C.G., Parise, C.B., Oliveira, J.R., Severino, B., Corvino, A., di Vaio, P., Temussi, P.A., Caliendo, G., Santagada, V., et al. (2017). Activity of human kallikrein-related peptidase 6 (KLK6) on substrates containing sequences of basic amino acids. Is it a processing protease? Biochim. Biophys. Acta 1865, 558–564.10.1016/j.bbapap.2017.02.017Search in Google Scholar PubMed

Singh, J.K., Simões, B.M., Howell, S.J., Farnie, G., and Clarke, R.B. (2013). Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 15, 210–219.10.1186/bcr3436Search in Google Scholar PubMed PubMed Central

Sotiropoulou, G. and Pampalakis, G. (2012). Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol. Sci. 33, 623–634.10.1016/j.tips.2012.09.005Search in Google Scholar PubMed

Sotiropoulou, G., Pampalakis, G., and Diamandis, E.P. (2009). Functional roles of human kallikrein-related peptidases. J. Biol. Chem. 284, 32989–32994.10.1074/jbc.R109.027946Search in Google Scholar PubMed PubMed Central

Stefanini, A.C., da Cunha, B.R., Henrique, T., and Tajara, E.H. (2015). Involvement of kallikrein-related peptidases in normal and pathologic processes. Dis. Markers 2015, 946572.10.1155/2015/946572Search in Google Scholar PubMed PubMed Central

Su, S., Li, Y., Luo, Y., Sheng, Y., Su, Y., Padia, R.N., Pan, Z.K., Dong, Z., and Huang, S. (2009). Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene 28, 3047–3057.10.1038/onc.2009.163Search in Google Scholar PubMed PubMed Central

Talieri, M., Diamandis, E.P., Gourgiotis, D., Mathioudaki, K., and Scorilas, A. (2004). Expression analysis of the human kallikrein 7 (KLK7) in breast tumors: a new potential biomarker for prognosis of breast carcinoma. Thromb. Haemost. 91, 180–186.10.1160/TH03-05-0261Search in Google Scholar PubMed

Talieri, M., Devetzi, M., Scorilas, A., Pappa, E., Tsapralis, N., Missitzis, I., and Ardavanis, A. (2011). Human kallikrein-related peptidase 12 (KLK12) splice variants expression in BC and their clinical impact. Tumor Biol. 33, 1075–1084.10.1007/s13277-012-0347-xSearch in Google Scholar PubMed

Teo, C.R., Casey, P.J., and Rasheed, S.A. (2016). The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins. Cell Signal. 28, 1479–1488.10.1016/j.cellsig.2016.07.001Search in Google Scholar PubMed

Têtu, B., Brisson, J., Wang, C.S., Lapointe, H., Beaudry, G., Blanchette, C., and Trudel, D. (2006). The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res. 8, R28–R37.10.1186/bcr1503Search in Google Scholar PubMed PubMed Central

Ullah, M.F. and Aatif, M. (2009). The footprints of cancer development: cancer biomarkers. Cancer Treat. Rev. 35, 193–200.10.1016/j.ctrv.2008.10.004Search in Google Scholar PubMed

Ulmert, D., O’Brien, M.F., Bjartell, A.S., and Lilja, H. (2009). Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat. Rev. Urol. 6, 384–391.10.1038/nrurol.2009.123Search in Google Scholar PubMed PubMed Central

van Winden, A.W., van den Broek, I., Gast, M.C., Engwegen, J.Y., Sparidans, R.W., van Dulken, E.J., Depla, A.C., Cats, A., Schellens, J.H., Peeters, P.H., et al. (2010). Serum degradome markers for the detection of breast cancer. J. Proteome Res. 9, 3781–3788.10.1021/pr100395sSearch in Google Scholar PubMed

Villanueva, J., Shaffer, D.R., Philip, J., Chaparro, C.A., Erdjument-Bromage, H., Olshen, A.B., Fleisher, M., Lilja, H., Brogi, E., Boyd, J., et al. (2006). Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116, 271–284.10.1172/JCI26022Search in Google Scholar PubMed PubMed Central

Vio, C.P., Roa, J.P., Silva, R., and Powers, C.A. (1990). Localization of immunoreactive glandular kallikrein in lactotrophs of the rat anterior pituitary. Neuroendocrinology 51, 10–14.10.1159/000125309Search in Google Scholar PubMed

Wang, S.M., Mao, J., Li, B., Wu, W., and Tang, L.L. (2008). Expression of KLK6 protein and mRNA in primary breast cancer and its clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 24, 1087–1099.Search in Google Scholar

Wang, Z., Ruan, B., Jin, Y., Zhang, Y., Li, J., Zhu, L., Xu, W., Feng, L., Jin, H., and Wang, X. (2016). Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer. Oncotarget 7, 79494–79502.10.18632/oncotarget.13104Search in Google Scholar PubMed PubMed Central

Webber, M.M., Waghray, A., and Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1, 1089–1094.Search in Google Scholar

Xing, R.H., Mazar, A., Henkin, J., and Rabbani, S.A. (1997). Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res. 57, 3585–3593.Search in Google Scholar

Yang, F., Aubele, M., Walch, A., Gross, E., Napieralski, R., Zhao, S., Ahmed, N., Kiechle, M., Reuning, U., Dorn, J., et al. (2017). Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biol. Chem. 398, 1151–1164.10.1515/hsz-2017-0122Search in Google Scholar

Ying, D., Stephens, C., Walpole, C., Swedberg, J.E., Boyle, G.M., Parsons, P.G., McGuckin, M.A., Harris, J.M., and Clements, J.A. (2013). Paclitaxel resistance and multicellular spheroid formation are induced by kallikrein-related peptidase 4 in serous ovarian cancer cells in an ascites mimicking microenvironment. PLoS One 8, e57056.10.1371/journal.pone.0057056Search in Google Scholar

Yoon, S.Y., Lee, Y.J., Seo, J.H., Sung, H.J., Park, K.H., Choi, I.K., Kim, S.J., Oh, S.C., Choi, C.W., Kim, B.S., et al. (2006). uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. Cell Res. 16, 75–81.10.1038/sj.cr.7310010Search in Google Scholar

Yousef, G.M., Luo, L.Y., Scherer, S.W., Sotiropoulou, G., and Diamandis, E.P. (1999). Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics 62, 251–259.10.1006/geno.1999.6012Search in Google Scholar

Yousef, G.M., Magklara, A., and Diamandis, E.P. (2000). KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69, 331–341.10.1006/geno.2000.6346Search in Google Scholar

Yousef, G.M., Magklara, A., Chang, A., Jung, K., Katsaros, D., and Diamandis, E.P. (2001). Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res. 61, 3425–3431.Search in Google Scholar

Yousef, G.M., Borgoño, C.A., Scorilas, A., Ponzone, R., Biglia, N., Iskander, L., Polymeris, M.E., Roagna, R., Sismondi, P., and Diamandis, E.P. (2002a). Quantitative analysis of human kallikrein gene 14 expression in breast tumours indicates association with poor prognosis. Br. J. Cancer 87, 1287–1293.10.1038/sj.bjc.6600623Search in Google Scholar

Yousef, G.M., Obiezu, C.V., Jung, K., Stephan, C., Scorilas, A., and Diamandis, E.P. (2002b). Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. Urology 60, 714–728.10.1016/S0090-4295(02)01811-3Search in Google Scholar

Yousef, G.M., Polymeris, M.E., Grass, L., Soosaipillai, A., Chan, P.C., Scorilas, A., Borgoño, C., Harbeck, N., Schmalfeldt, B., Dorn, J., et al. (2003). Human kallikrein 5: a potential novel serum biomarker for breast and ovarian cancer. Cancer Res. 63, 3958–3965.Search in Google Scholar

Yousef, G.M., Yacoub, G.M., Polymeris, M.E., Popalis, C., Soosaipillai, A., and Diamandis, E.P. (2004). Kallikrein gene downregulation in breast cancer. Br. J. Cancer 90, 167–172.10.1038/sj.bjc.6601451Search in Google Scholar PubMed PubMed Central

Yousef, G.M., White, N.M., Michael, I.P., Cho, J.C., Robb, J.D., Kurlender, L., Khan, S., and Diamandis, E.P. (2005). Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour Biol. 26, 227–235.10.1159/000087377Search in Google Scholar PubMed

Yu, H., Levesque, M.A., Clark, G.M., and Diamandis, E.P. (1999). Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br. J. Cancer 81, 490–495.10.1038/sj.bjc.6690720Search in Google Scholar PubMed PubMed Central

Zarzynska, J.M. (2014). Two faces of TGF-β1 in breast cancer. Mediators Inflamm. 2014, 14174710.1155/2014/141747Search in Google Scholar PubMed PubMed Central

Zhang, Y., Bhat, I., Zeng, M., Jayal, G., Wazer, D.E., Band, H., and Band, V. (2006). Human kallikrein 10, a predictive marker for breast cancer. Biol. Chem. 387, 715–721.10.1515/BC.2006.090Search in Google Scholar PubMed

Zhao, Y. and Adjei, A. (2015). Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 6, 660–673.10.1634/theoncologist.2014-0465Search in Google Scholar PubMed PubMed Central